LONDON & BOSTON & TOKYO--(BUSINESS WIRE)--#biopharma--The top 600 biopharma firms added $487 billion in market capitalisation in 2020, according to the Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review report, published today. Companies developing COVID-19 treatments experienced some of the largest gains; the greatest market cap increases by percentage were Novovax (2,702%) and South Korea�s Shin Poong (1,613%).

2020 also saw an unprecedented amount of cash flow into the sector. Drug developers raised a record-breaking $12.7 billion via IPO. This was more than twice the total raised in 2019, and the average amount raised ($167 million) nearly doubled. Private companies also broke records, with an astonishing $20bn invested by venture financers, although the total number of financing rounds was lower than in prior years.

For medical device makers, 2020 delivered split outcomes. The most successful large-cap companies like Teladoc and Novocure saw share prices double, but others like Boston Scientific and Becton Dickinson saw double-digit losses. Privately-held device companies benefitted from an influx of venture capital with a total of $6.4 billion, and medtech IPOs were generally well-received.

�The pandemic shone a spotlight on the drug development sector and investor interest drove pharma and biotech to new heights in 2020,� said report author Amy Brown. �This has set expectations quite high, and many richly-valued companies are under pressure to deliver in 2021.�

Other Report Highlights:

• AbbVie saw the largest increase in market cap by value, adding $58.2bn, followed by Eli Lilly ($35.3bn) and Moderna ($34.8bn).
• GlaxoSmithKline saw the greatest share price loss among big pharma (-25%), followed by Merck & Co (-12%) and Bristol Myers Squibb (-10%).
• Biopharma M&A transactions totaled $130bn, with deals announced by Astrazeneca, Gilead and Bristol Myers Squibb compensating for a slow start.
• The FDA approved 57 novel medicines with $21.6 billion in fifth-year sales potential.
• Medtech M&A continued to decline, closing 111 transactions totaling $27.3 billion, the lowest value since 2013.
• The average size of medtech venture financing rounds reached a ten-year high at $37.4 million, a 50% increase from 2019.
• The FDA approved 22 PMAs and 37 501(k) clearances, consistent with 2019 totals.

To download a complimentary copy of the report, visit https://www.evaluate.com/2020Review.

About Evaluate

Evaluate provides trusted commercial intelligence and predictive analytics for the pharmaceutical industry and their advisors.

Our Evaluate Omnium and EvaluatePharma^� platforms offer unique and dynamic insights into pharma asset risk and commercial potential alongside a seamless, comprehensive view of the pharmaceutical market landscape.

Evaluate Vantage � our award-winning, independent editorial team � provides thought-provoking news and insights into current and future industry developments.

Evaluate has been a partner to industry-leading organisations for 25 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com.

Follow us on Twitter: @EvaluatePharma, @EvaluateVantage

Contacts

Media:
Jennifer Dinkel

+1 617-936-7783

[email protected]